Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects.

Phage therapy has a long tradition in Eastern Europe, where preparations are comprised of complex phage cocktails whose compositions have not been described. We investigated the composition of a phage cocktail from the Russian pharmaceutical company Microgen targeting Escherichia coli/Proteus infections. Electron microscopy identified six phage types, with numerically T7-like phages dominating over T4-like phages. A metagenomic approach using taxonomical classification, reference mapping and de novo assembly identified 18 distinct phage types, including 7 genera of Podoviridae, 2 established and 2 proposed genera of Myoviridae, and 2 genera of Siphoviridae. De novo assembly yielded 7 contigs greater than 30 kb, including a 147-kb Myovirus genome and a 42-kb genome of a potentially new phage. Bioinformatic analysis did not reveal undesired genes and a small human volunteer trial did not associate adverse effects with oral phage exposure.

• Publication year

  2013

• Venue

  Virology

• Publication date

  2013-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.virol.2013.05.022PMID 23755967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The evolving threat of antimicrobial resistance: Options for action

  2014cited by this paper
• Bacteriophage-host interaction: from splendid isolation into a messy reality.

  2013cited by this paper
• Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice.

  2012cited by this paper
• Current opportunities and challenges in microbial metagenome analysis—a bioinformatic perspective

  2012cited by this paper
• Identification of a Novel Bat Papillomavirus by Metagenomics

  2012cited by this paper
• Isolation and characterization of a novel indigenous intestinal N4-related coliphage vB_EcoP_G7C.

  2012cited by this paper
• Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh.

  2012cited by this paper
• A Multivalent Adsorption Apparatus Explains the Broad Host Range of Phage phi92: a Comprehensive Genomic and Structural Analysis

  2012cited by this paper
• Virulent Bacteriophages Can Target O104:H4 Enteroaggregative Escherichia coli in the Mouse Intestine

  2012cited by this paper
• What is needed for phage therapy to become a reality in Western medicine?

  2012cited by this paper
• Complete Genome Sequence of the Novel Escherichia coli Phage phAPEC8

  2012cited by this paper
• Going viral: next-generation sequencing applied to phage populations in the human gut

  2012cited by this paper
• Introduction to the analysis of environmental sequences: metagenomics with MEGAN.

  2012cited by this paper
• Genomic and Proteomic Characterization of the Broad-Host-Range Salmonella Phage PVP-SE1: Creation of a New Phage Genus

  2011cited by this paper
• Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome

  2011cited by this paper
• Broad Surveys of DNA Viral Diversity Obtained through Viral Metagenomics of Mosquitoes

  2011cited by this paper
• Complete Genomic Sequence of Bacteriophage Felix O1

  2010cited by this paper
• Control of Bacterial Diarrhea with Phages: Coverage and Safety Issues in Bacteriophage Therapy

  2010cited by this paper
• Identification of lytic bacteriophage MmP1, assigned to a new member of T7-like phages infecting Morganella morganii.

  2010cited by this paper
• Viruses in the fecal microbiota of monozygotic twins and their mothers

  2010cited by this paper
• A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

  2010cited by this paper
• A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy

  2009cited by this paper
• Metagenomic Analysis of Respiratory Tract DNA Viral Communities in Cystic Fibrosis and Non-Cystic Fibrosis Individuals

  2009cited by this paper
• T4 phages against Escherichia coli diarrhea: potential and problems.

  2009cited by this paper
• Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials

  2009cited by this paper
• The genome and proteome of a virulent Escherichia coli O157:H7 bacteriophage closely resembling Salmonella phage Felix O1

  2009cited by this paper
• Metagenomic Analyses of Viruses in Stool Samples from Children with Acute Flaccid Paralysis

  2009cited by this paper
• Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

  2009cited by this paper
• Sequence analysis of Escherichia coli O157:H7 bacteriophage PhiV10 and identification of a phage-encoded immunity protein that modifies the O157 antigen.

  2009cited by this paper
• In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli.

  2009cited by this paper
• Modular architecture of the T4 phage superfamily: a conserved core genome and a plastic periphery.

  2007cited by this paper
• Genome Analysis of Phage JS98 Defines a Fourth Major Subgroup of T4-Like Phages in Escherichia coli

  2007cited by this paper
• Escherichia coli K1-Specific Bacteriophage CUS-3 Distribution and Function in Phase-Variable Capsular Polysialic Acid O Acetylation

  2007cited by this paper
• Viruses vs Superbugs: A Solution to the Antibiotic Crisis?

  2007cited by this paper
• Viruses vs. superbugs

  2006cited by this paper
• The Genome of the Novel Phage Rtp, with a Rosette-Like Tail Tip, IsHomologous to the Genome of Phage T1

  2006cited by this paper
• Phage therapy: the Escherichia coli experience.

  2005cited by this paper
• The Genome of Bacteriophage K1F, a T7-Like Phage That Has Acquired the Ability To Replicate on K1 Strains of Escherichia coli

  2005cited by this paper
• Genomic analysis of bacteriophages SP6 and K1-5, an estranged subgroup of the T7 supergroup.

  2004cited by this paper
• Bacteriophage Therapy in Humans

  2004cited by this paper
• Phages and the Evolution of Bacterial Pathogens: from Genomic Rearrangements to Lysogenic Conversion

  2004cited by this paper
• Bacteriophage T4 Genome

  2003cited by this paper
• Stalin's Forgotten Cure

  2002cited by this paper
• Genomic analysis of uncultured marine viral communities

  2002cited by this paper
• Bacteriophage SP6 Is Closely Related to Phages K1-5, K5, and K1E but Encodes a Tail Protein Very Similar to That of the Distantly Related P22

  2002cited by this paper
• Bacteriophage Therapy

  2001cited by this paper
• Contribution of dps to Acid Stress Tolerance and Oxidative Stress Tolerance in Escherichia coli O157:H7

  2000cited by this paper
• Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity.

  1998cited by this paper
• bor gene of phage lambda, involved in serum resistance, encodes a widely conserved outer membrane lipoprotein

  1995cited by this paper
• Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics.

  1982cited by this paper

• Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study.

  2026cites this paper
• Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods

  2026cites this paper
• Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice

  2025cites this paper
• Isolation and complete genome sequence of a novel Mycobacterium phage MS619

  2025cites this paper
• Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.

  2025cites this paper
• Novel strategies for vancomycin-resistant Enterococcus faecalis biofilm control: bacteriophage (vB_EfaS_ZC1), propolis, and their combined effects in an ex vivo endodontic model

  2025cites this paper
• Characterization of a novel phage PFX2 and its preliminary application in the biocontrol of Pseudomonas fluorescens biofilms on fresh beef.

  2025cites this paper
• Phage Therapy: Combating Evolution of Bacterial Resistance to Phages

  2025cites this paper
• The potential of bacteriophages in treating multidrug-resistant ESKAPE pathogen infections

  2025cites this paper
• Bacteria- and Phage-Derived Proteins in Phage Infection.

  2025cites this paper
• Phage therapy as a modern alternative to antibiotics

  2025cites this paper
• Cytokines Meet Phages: A Revolutionary Pathway to Modulating Immunity and Microbial Balance

  2025cites this paper
• Gut Virus Axis: Unravelling Viral Contribution to Gut Microbiota Dysbiosis and Translational Medicine in Inflammatory Bowel Disease (IBD)

  2025cites this paper
• A Century of Bacteriophages: Insights, Applications, and Current Utilization

  2025cites this paper
• Exploring the Potential of Lytic Phage Dsi15 with Broad Host Range for Controlling Salmonella in a Food Matrix

  2025cites this paper
• Development of Stabilizing Solution for Long-Term Storage of Bacteriophages at Room Temperature and Application to Control Foodborne Pathogens

  2024cites this paper
• Intestinal microecology dysbiosis in inflammatory bowel disease: Pathogenesis and therapeutic strategies

  2024cites this paper
• Isolation and characterization of Salmonella typhimurium lytic bacteriophages from fermented shrimp paste (Terasi)

  2024cites this paper
• Antibacterial and antifouling materials for urinary catheter coatings.

  2024cites this paper
• Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial

  2024influential citation
• Pseudomonas aeruginosa Bacteriophages and Their Clinical Applications

  2024cites this paper
• Dietary Bacteriophage Administration Alleviates Enterotoxigenic Escherichia coli-Induced Diarrhea and Intestinal Impairment through Regulating Intestinal Inflammation and Gut Microbiota in a Newly Weaned Mouse Model

  2024cites this paper
• Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages

  2024cites this paper
• Comparison of Crohn’s disease-associated adherent-invasive Escherichia coli (AIEC) from France and Hong Kong: results from the Pacific study

  2024cites this paper
• A mini-review on the role of bacteriophages in food safety

  2024cites this paper
• An effective antibiofilm strategy based on bacteriophages armed with silver nanoparticles

  2024cites this paper
• Metagenomic analyses of single phages and phage cocktails show instances of contamination with temperate phages and bacterial DNA

  2024cites this paper
• Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections

  2024cites this paper
• A Critical Analysis of the Opportunities and Challenges of Phage Application in Seafood Quality Control

  2024cites this paper
• Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections

  2024cites this paper
• Bacteriophage Production in Compliance with Regulatory Requirements.

  2024cites this paper
• Phage Therapy for Bone and Joint Infections: A Comprehensive Exploration of Challenges, Dynamics, and Therapeutic Prospects.

  2024cites this paper
• Rapid Bench to Bedside Therapeutic Bacteriophage Production.

  2024cites this paper
• Sxt1, Isolated from a Therapeutic Phage Cocktail, Is a Broader Host Range Relative of the Phage T3

  2024cites this paper
• Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization

  2023cites this paper
• The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria

  2023cites this paper
• Characterization of bacteriophage BUCT631 lytic for K1 Klebsiella pneumoniae and its therapeutic efficacy in Galleria mellonella larvae

  2023cites this paper
• Immunogenicity of bacteriophages.

  2023cites this paper
• Regulations of phage therapy across the world

  2023cites this paper
• In ovo administration of a phage cocktail partially prevents colibacillosis in chicks

  2023cites this paper
• Fitness-Conditional Genes for Soil Adaptation in the Bioaugmentation Agent Pseudomonas veronii 1YdBTEX2

  2023cites this paper
• Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens

  2023cites this paper
• Characterization, genome analysis and antibiofilm efficacy of lytic Proteus phages RP6 and RP7 isolated from university hospital sewage

  2023cites this paper
• The Future of Clinical Phage Therapy in the United Kingdom

  2023cites this paper
• Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa

  2023cites this paper
• Application of a novel lytic Jerseyvirus phage LPSent1 for the biological control of the multidrug-resistant Salmonella Enteritidis in foods

  2023cites this paper
• Isolation and Characterization of a Novel Phage Collection against Avian-Pathogenic Escherichia coli

  2023cites this paper
• Application of a novel phage LPCS28 for biological control of Cronobacter sakazakii in milk and reconstituted powdered infant formula.

  2023cites this paper
• The impact of phage treatment on bacterial community structure is minor compared to antibiotics

  2023cites this paper
• Translating phage therapy into the clinic: Recent accomplishments but continuing challenges

  2023cites this paper
• Modulation of Caecal Microbiota and Metabolome Profile in Salmonella-Infected Broilers by Phage Therapy

  2023cites this paper
• Phage therapy: Awareness and demand among clinicians in the United Kingdom

  2023cites this paper
• Bacteriophages and food safety: An updated overview

  2023cites this paper
• Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa

  2023cites this paper
• Phage therapy for diabetic foot infection

  2022cites this paper
• Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA)

  2022cites this paper
• Immunological and safety profile of bacteriophage therapy: A pre‐clinical study

  2022cites this paper
• Characterization of the Bacteriophage BUCT603 and Therapeutic Potential Evaluation Against Drug-Resistant Stenotrophomonas maltophilia in a Mouse Model

  2022cites this paper
• Characterization of the Lytic Phage Flora With a Broad Host Range Against Multidrug-Resistant Escherichia coli and Evaluation of Its Efficacy Against E. coli Biofilm Formation

  2022cites this paper
• Therapeutic efficacies of two newly isolated Edwardsiella phages against Edwardsiella piscicida infection.

  2022cites this paper
• Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era

  2022cites this paper
• Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.

  2022cites this paper
• A novel Bacillus cereus bacteriophage DLn1 and its endolysin as biocontrol agents against Bacillus cereus in milk.

  2022cites this paper
• The potential of bacteriophage therapy in the treatment of paediatric respiratory infections.

  2022cites this paper
• Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii

  2022cites this paper
• Paving the way for phage therapy using novel drug delivery approaches.

  2022cites this paper
• The resurgence of phage-based therapy in the era of increasing antibiotic resistance: From research progress to challenges and prospects.

  2022cites this paper
• [Analysis of genomic information and biological characteristics of a bacteriophage against methicillin-resistant Staphylococcus aureus in patients with median sternal incision infection].

  2022cites this paper
• Phage therapy: current review and future perspectives

  2022cites this paper
• Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans

  2022cites this paper
• Pathogenicity and virulence of Clostridioides difficile

  2022cites this paper
• Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review

  2022cites this paper
• Tracking the phage trends: A comprehensive review of applications in therapy and food production

  2022cites this paper
• The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials

  2022cites this paper
• Safety and Efficacy of an AIEC-targeted Bacteriophage Cocktail in a Mice Colitis Model.

  2022cites this paper
• Phage Therapy: A Potential Novel Therapeutic Treatment of MRSA

  2022cites this paper
• Genomic characterization of a novel bacteriophage STP55 revealed its prominent capacity in disrupting the dual-species biofilm formed by Salmonella Typhimurium and Escherichia coli O157: H7 strains

  2022cites this paper
• One-step salting-out extraction of bacteriophage from its infection broth of Acinetobacter baumannii.

  2022cites this paper
• Development and validation of a miniaturized host range screening assay for bacteriophages

  2021cites this paper
• Characterization of Anti-Bacterial Effect of the Two New Phages against Uropathogenic Escherichia coli

  2021cites this paper
• Bacteriophage Therapy: Recent Development and Applications

  2021cites this paper
• Bacteriophages as tools for biofilm biocontrol in different fields

  2021cites this paper
• Resistance and Adaptation of Bacteria to Non-Antibiotic Antibacterial Agents: Physical Stressors, Nanoparticles, and Bacteriophages

  2021cites this paper
• Advances in Phage Therapy: Targeting the Burkholderia cepacia Complex

  2021cites this paper
• Antibiotics at the crossroads – Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?

  2021cites this paper
• The Safety and Toxicity of Phage Therapy: A Review of Pre-Clinical and Clinical Studies

  2021cites this paper
• Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?

  2021cites this paper
• Microbiome in Human Gastrointestinal Cancers

  2021cites this paper
• Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective

  2021cites this paper
• Bacteriophages and their potential for treatment of gastrointestinal diseases

  2021cites this paper
• Integrating Viral Metagenomics into an Ecological Framework.

  2021cites this paper
• Non‐bacteria microbiome (virus, fungi, and archaea) in gastrointestinal cancer

  2021cites this paper
• Phage Therapy: A Potential Novel Therapeutic Treatment of Methicillin-Resistant Staphylococcus aureus

  2021cites this paper
• Isolation, characterization, and application of Salmonella paratyphi phage KM16 against Salmonella paratyphi biofilm

  2021cites this paper
• Intestinal virome and therapeutic potential of bacteriophages in liver disease.

  2021cites this paper
• Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosa.

  2021cites this paper
• The role of phage therapy in burn wound infection management: advantages and pitfalls.

  2021cites this paper
• Bacteriophage Pharmacology and Immunology

  2021cites this paper
• Isolation of a Virulent Aeromonas salmonicida subsp. masoucida Bacteriophage and Its Application in Phage Therapy in Turbot (Scophthalmus maximus)

  2021cites this paper
• Isolation of Diarrheagenic Escherichia coli and their Specific Phages from Rabbits

  2021cites this paper